Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Irina Amitai, Ilana Hellmann, Maya Koren-Michowitz, Tsila Zuckerman, Ariel Aviv, Anatoly Nemets, Itai Levi, Yishai Ofran, Moshe Mittelman, Drorit Grizim Merkel

Blood (2022) 140 (Supplement 1): 12349–12350.

https://doi.org/10.1182/blood-2022-166542

Published: 2022

Journal Articles

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Rachel Burstein, Adir Shaulov, Dina Ben Yehuda, Boaz Nachmias, Moshe E Gatt, Ariel Aviv

Blood (2022) 140 (Supplement 1): 10793.

https://doi.org/10.1182/blood-2022-162541

Published: 2022

Journal Articles

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion

Blood (2022) 140 (Supplement 1): 11947–11948.

https://doi.org/10.1182/blood-2022-159881

Published: 2022

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

Journal Articles

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini

Blood (2021) 138 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2021-146504

Published: 2021

Journal Articles

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

Naseba Naseraldeen, M.A., Regina Michelis, D.Sc, Masad Barhoum, MD, Judith Chezar, PhD, Tamar Tadmor, MD, Ariel Aviv, MD, Lev Shvidel, MD, Adi Litmanovich, Mona Yuklea, MD, Mona Shehadeh, PhD, Ety Shaoul, PhD, Andrei Braester, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141198

Published: 2020

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Anat Gafter-Gvili, MD, Elena Ribakovsky, MD, Nadav Mizrahi, Abraham Avigdor, MD, Ariel Aviv, MD, Liat Vidal, MDMSc, Ron Ram, MD, Arnon Nagler, MD, Pia Raanani, MD, Ronit Gurion, MD

Blood (2014) 124 (21): 3077.

https://doi.org/10.1182/blood.V124.21.3077.3077

Published: 2014

Journal Articles

Cancer Registries Often Underestimate the True Incidence of CLL

Rosa Ruchlemer, MD, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, MD MPH, Ariel Aviv, MD, Ariella Arad, MD, Osnat Bairey, MD, Ohad Binyamini, MD, Andre Braester, MD, Riva Fineman, MD, Neta Goldshmidt, MD, Yair Herishanu, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Mona Yuklea, MD, Aaron Polliack, MD, Lital Keinan-Boker, MD PhD MPH

Blood (2014) 124 (21): 5646.

https://doi.org/10.1182/blood.V124.21.5646.5646

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Yair Herishanu, MD, Neta Goldschmidt, MD, Osnat Bairey, MD, Rosa Ruchlemer, MD, Riva Fineman, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Ariel Aviv, MD, Andrei Braester, MD, Erel Joffe, MDMSc, Aaron Polliack, MD

Blood (2014) 124 (21): 5659.

https://doi.org/10.1182/blood.V124.21.5659.5659

Published: 2014

Journal Articles

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Tamar Tadmor, MD, Riva Fineman, MD, Lev Shvidel, Osnat Bairey, MD, Neta Goldschmidt, MD, Rosa Ruchlemer, Naomi Rahimi Rachimi, MD, Yair Herishanu, MD, Mona Yuklea, MD,, Ariela Arad, MD, Ariel Aviv, MD, Aaron Polliack, MD

Blood (2013) 122 (21): 5281.

https://doi.org/10.1182/blood.V122.21.5281.5281

Published: 2013

Journal Articles

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Drorit Merkel, MD, Kalman Filanovsky, MD, Ariel Aviv, MD, Moshe E. Gatt, MD, Yair Herishanu, MD, Ariela Arad, MD, Tamar Tadmor, MD, Najib Dally, MD, Aharon Ronson, MD, Luiza Akria, MD, Andrei Braester, MD, Arnon Nagler, MD, Ronit Leiba, MSc., Yishai Ofran, MD

Blood (2011) 118 (21): 3811.

https://doi.org/10.1182/blood.V118.21.3811.3811

Published: 2011

NARROW

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Cancer Registries Often Underestimate the True Incidence of CLL

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only